Molecular assessment of the potential for renal drug interactions between tenofovir and HIV protease inhibitors

Antiviral Therapy

Volumn 12, Issue 2, 2007, Pages 267-272

  Cihlar, Tomas ^a   Ray, Adrian S ^a   Laflamme, Genevieve ^a   Vela, Jennifer E ^a   Tong, Leah ^a   Fuller, Michael D ^a   Roy, Anupma ^a,b   Rhodes, Gerald R ^a  

^a GILEAD SCIENCES   (United States)

^b Telic Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMPRENAVIR; ATAZANAVIR; LOPINAVIR; LOPINAVIR PLUS RITONAVIR; MULTIDRUG RESISTANCE PROTEIN 2; MULTIDRUG RESISTANCE PROTEIN 4; NELFINAVIR; ORGANIC ANION TRANSPORTER 1; ORGANIC ANION TRANSPORTER 3; ORGANIC ANION TRANSPORTER 4; PROTEINASE INHIBITOR; RITONAVIR; SAQUINAVIR; TENOFOVIR; TENOFOVIR DISOPROXIL;

ANIMAL CELL; ARTICLE; CELL TRANSPORT; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYTOTOXICITY; DRUG EFFECT; DRUG TRANSPORT; HUMAN; HUMAN CELL; IN VITRO STUDY; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN EXPRESSION;

ADENINE; ANIMALS; CELL SURVIVAL; CHO CELLS; CRICETINAE; CRICETULUS; DOGS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG INTERACTIONS; HIV PROTEASE INHIBITORS; HUMANS; INHIBITORY CONCENTRATION 50; KIDNEY; MULTIDRUG RESISTANCE-ASSOCIATED PROTEINS; ORGANIC ANION TRANSPORT PROTEIN 1; ORGANIC ANION TRANSPORTERS, SODIUM-INDEPENDENT; PHOSPHONIC ACIDS; REVERSE TRANSCRIPTASE INHIBITORS; TIME FACTORS; TRANSFECTION;

EID: 34147173854     PISSN: 13596535     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (22)

1. Kearney BP, Flaherty JF, Shah J. Tenofovir disoproxil fumarate: clinical pharmacology and pharmacokinetics. Clin Pharmacokinet 2004; 43:595-612.
2. Cihlar T, Ho ES, Lin DC, Mulato AS. Human renal organic anion transporter 1 (hOAT1) and its role in the nephrotoxicity of antiviral nucleotide analogs. Nucleosides Nucleotides Nucleic Acids 2001; 20:641-648.
3. Cihlar T, Bleasby K, Roy A, Pritchard J. Antiviral acyclic nucleotide analogs tenofovir and adefovir are substrates for kidney organic anion, but not cation transporters: Implications for renal drug interactions. 44th Interscience Conference on Antimicrobial Agents and Chemotherapy, 30 October - 2 November 2004, Washington DC, USA. Abstract A-443.
4. Lee W, Kim R. Transporters and renal drug elimination. Annu Rev Pharmacol Toxicol 2004; 44:137-166.
5. Rollot F, Nazal EM, Chauvelot-Moachon L, et al. Tenofovir-related Fanconi syndrome with nephrogenic diabetes insipidus in a patient with acquired immunodeficiency svndrome: the role of lopinavir-ritonavir-didanosine. Clin Infect Dis 2003; 37:e174-e176.
6. Zimmermann AE, Pizzoferrato T, Bedford J, Morris A, Hoffman R, Braden G. Tenofovir-associated acute and chronic kidney disease: a case of multiple drug interactions. Clin Infect Dis 2006; 42:283-290.
7. Ray AS, Cihlar T, Robinson KL, et al. Mechanism of active renal tubular efflux of tenofovir. Antimicrobial Agents Chemother 2006; 50:3297-3304.
8. Imaoka T, Kusuhara H, Adachi M, Schuetz JD, Takeuchi K, SugiyamaY. Functional involvement of multidrug resistance-association protein 4 (MRP4/ABCC4) in the renal elimination of the antiviral drugs adefovir and tenofovir, Mol Pharmacol 2007 71:619-627.
9. Kearney BP, Mathias A, Mittan A, Sayre J, Ebrahimi R, Cheng AK. Pharmacokinetics and safety of tenofovir disoproxil fumarate on coadministration with lopinavir/ritonavir. J Acquir Immune Defic Syndr. 2006; 43:278-283.
10. Lee CG, Gottesman MM, Cardarelli CO, et al. HIV-1 protease inhibitors are substrates for the MDR1 multidrug transporter. Biochemistry 1998; 37:3594-3601.
11. Huisman MT, Smit JW, Crommentuyn KM, et al. Multidrug resistance protein 2 (MRP2) transports HIV protease inhibitors, and transport can be enhanced by other drugs. AIDS 2002; 16:2295-2301.
12. Izzedine H, Launay-Vacher V, Deray G Antiviral drug-induced nephrotoxicity. Am J Kidney Dis 2005; 45:804-817.
13. Louie SG, Lam J, Neely M, Beringer P. Multidrug resistance protein-2 (MRP2) inhibition by ritonavir increases tenofovir-associated renal epithelial cell cytotoxicity. 3rd International AIDS Society Conference on HIV Pathogenesis and Treatment; Rio de Janeiro, Brazil, 2005; Abstract WePe3.3C09
14. Louie SG, Lam J, Neely M, Beringer P. Multidrug resistance protein-2 (MRP2) inhibition by ritonavir increases tenorovir-associated renal epithelial cell cytotoxicity. 6th International Workshop on Clinical Pharmacology of HIV Therapy; Quebec, Canada; 2005. Abstract 2.16.
15. Ho ES, Lin DC, Mendel DB, Cihlar T. Cytotoxicity of antiviral nucleotides adefovir and cidofovir is induced by the expression of human renal organic anion transporter 1. J Am Soc Nephrol 2000; 11:383-393.
16. Schuetz JD, Connelly MC, Sun D, et al. MRP4: A previously unidentified factor in resistance to nucleoside-based antiviral drugs. Nat Med 1999; 5:1048-1051.
17. Ray AS, Myrick F, Vela JE, et al. Lack of a metabolic and antiviral drug interaction between tenofovir, abacavir and lamivudine. Antivir Ther 2005; 10:451-457.
18. Evers R, Kool M, Smith AJ, van Deemter L, de Haas M, Borst P. Inhibitory effect of the reversal agents V-104, GF120918 and Pluronic L61 on MDR1 Pgp-, MRP1- and MRP2-mediated transport. Br J Cancer 2000; 83:366-374.
19. Boffito M, Back D, Blaschke T, et al. Protein binding in antiretroviral therapies. AIDS Res Hum Retroviruses 2003; 19:825-835.
20. Johnson M, Grinsztejn B, Rodriguez C, et al. 96-week comparison of once-daily atazanavir/ritonavir and twice-daily lopinavir/ritonavir in patients with multiple virologic failures. AIDS 2006; 20:711-718.
21. van Gelder J, Deferme S, Naesens L, et al. Intestinal absorption enhancement of the ester prodrug tenofovir disoproxil fumarate through modulation of the biochemical barrier by defined ester mixtures. Drug Metab Dispos 2002; 30:924-930.
22. Ray AS, Tong L, Robinson KL, Kearney BP, Rhodes GR. Role of intestinal absorption in increased tenofovir exposure when tenofovir disoproxil fumarate is co-adminstered with atazanavir or lopinavir/ritonavir. 7th International Workshop on Clinical Pharmacology of HIV Therapy, 20-22 April 2006, Lisbon, Portugal. Abstract 49.